Use of olmesartan and enteropathy outcomes: a multi-database study.

Yaa-Hui DongY JinT N TsacogianisM HeP-H HsiehJ J Gagne

Published in: Alimentary pharmacology & therapeutics (2018)

This large-scale, multi-database study found a higher rate of enteropathy in olmesartan initiators as compared to initiators of other ARBs, although the absolute incidence rate was low in both groups.

Keyphrases

risk factors
adipose tissue
metabolic syndrome
adverse drug